First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.
Simple Summary: Treatment of patients with mantle cell lymphoma is rapidly evolving, driven by several recent clinical trials showing that combining covalent Bruton's tyrosine kinase inhibitors with other therapies can lead to improved outcomes. Although these newer treatment approaches expand avail...
| Publicado en: | Current Oncology Vol. 33; no. 7; pp. 426 - 446 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195807458&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195807458 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Jul2026 vid: 33 iid: 7 pid: 97109 pub: MDPI artinfo: ui: 195807458 10.3390/curroncol33070426 195807458 ppf: 426 ppct: 20 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma. aug: au: Puckrin, Robert Villa, Diego Fleury, Isabelle Larouche, Jean-François Kuruvilla, John affil: Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada sug: ab: Simple Summary: Treatment of patients with mantle cell lymphoma is rapidly evolving, driven by several recent clinical trials showing that combining covalent Bruton's tyrosine kinase inhibitors with other therapies can lead to improved outcomes. Although these newer treatment approaches expand available options and offer greater flexibility, choosing the best therapy has become more complex. Optimal treatment selection increasingly requires a personalized approach that considers disease features, patient health and preferences, and local factors such as access to care. In this paper, we present three patient cases to illustrate how these factors influence decision-making and to highlight the practical considerations involved in selecting among standard and emerging first-line covalent Bruton's tyrosine kinase inhibitor-based combinations. First-line (1L) therapy for mantle cell lymphoma (MCL) continues to evolve rapidly, with several recent phase II and phase III trials consistently showing the activity of novel covalent Bruton's tyrosine kinase inhibitor (cBTKi) combinations. Historical treatment selection criteria such as patient age, fitness, and eligibility for autologous stem cell transplantation generally remain applicable for some, but not all, of these novel regimens. This potential for flexibility necessitates the consideration of additional factors during decision-making, such as MCL biology, patient risk tolerance, logistical and resource implications, and the impact on use of later-line options. This paper presents three illustrative patient cases to explore 1L therapy selection among these new and emerging cBTKi options. The realized and anticipated benefits, limitations, and challenges and persisting evidence gaps associated with these regimens are discussed. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|